The aim of the Netherlands Society of Gene & Cell Therapy is to promote both fundamental and translational research on gene & cell therapies. By bringing together all stakeholders (i.e. researchers, patients, physicians, government and regulatory authorities) the society aims to contribute to the swift development of new therapies for life-threatening diseases, including inherited diseases as well as acquired diseases such as cancer and cardiovascular diseases.

To achieve this, the society actively promotes:

  • Exchange of information and expertise between the various stakeholders
  • Public awareness of the status and possibilities of gene & cell therapy by organizing public events, workshops and lectures
  • Educational & Research-oriented sessions for researchers in the gene & cell therapy field (e.g. organisation of Spring Symposium)

Our Sponsors


Cel- en gentherapie in opkomst maar toepassing kent belemmeringen – ZonMw

De komende jaren komen voor verschillende vormen van kanker en andere ernstige ziekten behandelingen met celtherapie en gentherapie beschikbaar. Met deze zogenoemde advanced therapy medicinal products (ATMP’s) kunnen bijvoorbeeld afweercellen van de patiënt worden bewerkt om een tumor te herkennen en uit te schakelen. Een andere veelbelovende ontwikkeling is gentherapie voor zeldzame aandoeningen als hemofilie B. Deze …

EC Approves Novartis’ Kymriah CAR-T Cell Therapy | BioPharm International

The European Commission (EC) has approved Novartis’ chimeric antigen receptor T cell (CAR-T) cell therapy Kymriah for the treatment of B-cell acute lymphoblastic leukemia and relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. Source: EC Approves Novartis’ Kymriah CAR-T Cell Therapy | BioPharm International